Derivation of an Annualized Claims-Based Major Adverse Cardiovascular Event Estimator in Type 2 Diabetes
Authors' conclusion
ACME was derived in a large usual care population, relies on routinely available data, and estimates short-term MACE risk.
Study context
- Population
- Adults with T2DM in commercial, Medicare Advantage and Medicare fee-for-service plans, 2014–2021
- Participants
- 6,623,526 adults
- Outcome
- MACE (nonfatal acute MI, nonfatal stroke, all-cause mortality) predicted by the ACME model
- Follow-up
- 1 year
Methodological detailsclaims-based, Cox proportional hazards model, 30 covariates
- Claims-based
- Cox proportional hazards model
- 30 covariates
Performance
As reported in the abstract
Discrimination of ACME
Concordance index (validation index range: 0.739-0.741)
0.74
Further findings
Predicted 1-year major adverse cardiovascular events (MACE) risk in the study cohort
- Median predicted risk (IQR: 2.3%-6.5%)
- 3.4%
- Range of predicted risk
- 0.4% to 99.9%
Original publication
Derivation of an Annualized Claims-Based Major Adverse Cardiovascular Event Estimator in Type 2 Diabetes. JACC Adv. Published 21 February 2024. doi:10.
Summarised from the published abstract; every number is checked against it